Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30237334 | 0.86 | BRPF1 (0.35) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL3102060 | 0.86 | BRPF1 (0.35) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL28980751 | 0.83 | BRPF1 (0.37) | NCOA1NCOA3BRPF1CA12BRD4 | |
| SCHEMBL20582363 | 0.82 | CDK4 (0.34) | KDM4EALDH1A1HPGDNCOA1NCOA3 | |
| SCHEMBL3113411 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDSRD5A1MEN1 | |
| SCHEMBL20582346 | 0.80 | SRD5A1 (0.33) | ALDH1A1SRD5A1 | |
| SCHEMBL21820280 | 0.80 | ALDH1A1 (0.37) | KDM4EALDH1A1HPGDNCOA1NCOA3 | |
| SCHEMBL20582441 | 0.79 | — | — | |
| SCHEMBL20582362 | 0.78 | BRPF1 (0.33) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL30236938 | 0.78 | BRPF1 (0.33) | BRPF1CA12BRD4CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110382505-B | Heterocyclic compounds useful as antibacterial agents and process for producing the same | 巴格沃克斯研究有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| EP-2029612-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | UROD, ALPI, HLA-A | KDM4E 4467/4885ALDH1A1 1655/4885HPGD 88/4885 |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | KDM4E 1893/4885ALDH1A1 2362/4885HPGD 2256/4885 |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | UROD, ALPI, HLA-A | KDM4E 4467/4885ALDH1A1 1655/4885HPGD 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.